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Background. Coronavirus disease 2019 (COVID-19) can result in profound changes in blood coagulation. The aim of the study was
to determine the incidence and predictors of venous thromboembolic events (VTE) among patients with COVID-19 requiring
hospital admission. Subjects and Methods. We performed a retrospective study at the Lausanne University Hospital with
patients admitted because of COVID-19 from February 28 to April 30, 2020. Results. Among 443 patients with COVID-19, VTE
was diagnosed in 41 patients (9.3%; 27 pulmonary embolisms, 12 deep vein thrombosis, one pulmonary embolism and deep
vein thrombosis, one portal vein thrombosis). VTE was diagnosed already upon admission in 14 (34.1%) patients and 27
(65.9%) during hospital stay (18 in ICU and nine in wards outside the ICU). Multivariate analysis revealed D-dimer value >
3,120 ng/ml (P < 0:001; OR 15.8, 95% CI 4.7-52.9) and duration of 8 days or more from COVID-19 symptoms onset to
presentation (P 0.020; OR 4.8, 95% CI 1.3-18.3) to be independently associated with VTE upon admission. D-dimer value ≥
3,000 ng/l combined with a Wells score for PE ≥ 2 was highly specific (sensitivity 57.1%, specificity 91.6%) in detecting VTE
upon admission. Development of VTE during hospitalization was independently associated with D-dimer value > 5,611 ng/ml
(P < 0:001; OR 6.3, 95% CI 2.4-16.2) and mechanical ventilation (P < 0:001; OR 5.9, 95% CI 2.3-15.1). Conclusions. VTE seems
to be a common COVID-19 complication upon admission and during hospitalization, especially in ICU. The combination of
Wells ≥ 2 score and D − dimer ≥ 3,000 ng/l is a good predictor of VTE at admission.
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1. Introduction
Coronavirus disease 2019 (COVID-19) refers to the infection
caused by the Severe Acute Respiratory Syndrome Coronavi-
rus 2 (SARS-CoV-2), which was first reported in December
2019 in Wuhan, China, and subsequently spread worldwide
rapidly gaining pandemic proportions, causing a large spec-
trum of manifestations varying from asymptomatic disease
and mild respiratory symptoms to severe infection and death
[1–3]. Profound changes in blood coagulation of these
patients have already been described [4–6], and elevated D-
dimer values upon admission have been recognized as a pre-
dictor of mortality [7, 8]. Even though the exact nature of the
association between elevated D-dimer values and worse out-
comes is not yet fully elucidated, venous thromboembolic
events (VTE) could contribute to the higher morbidity and
mortality of these patients.
Data on the association between SARS-CoV-2 and VTE
are continuously emerging. Several studies have described
the high incidence of VTE during severe SARS-CoV-2 infec-
tion in patients hospitalized in the Intensive Care Unit (ICU)
[9–13], but data regarding the earlier stages of the disease or
patients with less severe disease are still limited [11, 14]. In
addition, it remains uncertain whether the SARS-CoV-2
infection is independently associated with an increased risk
of VTE.
Activation of platelets and coagulation pathways are
likely induced by the massive release of proinflammatory
mediators reflected by the highly elevated inflammatory bio-
markers during the course of the SARS-CoV-2 infection. The
particular role of cytokines, such as TNF-α, IL-6, and the
inhibitory cytokine IL-10, in association with a quantitative
and functional lymphocyte dysregulation, for COVID-19
severity has been postulated by some studies [15, 16]. These
features along with the loss of the normal antithrombotic
and anti-inflammatory functions of endothelial cells and
the leukocyte recruitment in the microvasculature, com-
monly described as thromboinflammation, seem to partici-
pate in the pathogenesis of thrombosis during COVID-19,
in a way similar to sepsis [17, 18].
Our study is aimed at providing a thorough descriptive
analysis of VTE occurring in distinct groups of patients
according to the timing of presentation (upon admission,
during hospitalization), in order to determine the VTE pre-
dictors and to evaluate the diagnostic performance of clinical
scores and biomarkers. We also aim to assess the impact of
the early VTE identification and the intensification of pre-
ventive anticoagulation strategies.
2. Subjects and Methods
This retrospective study was conducted at Lausanne Univer-
sity Hospital, a 1,500-bed tertiary care hospital and one of the
five medical teaching hospitals in Switzerland. Adult patients
with microbiologically documented SARS-CoV-2 infection
admitted from February 28 to April 30, 2020, were included
with a follow-up until May 5, 2020. SARS-CoV-2 infection
was proven by real-time PCR, as previously described [19].
This work was performed as part of the COVID-19 Interdis-
ciplinary Collaboration (the COVIDIC Initiative). The study
was approved by the ethics committee of the Canton of Vaud
(CER-VD 2020-00815) that exceptionally waived the need
for informed consent allowing the inclusion of all hospital-
ized COVID-19 patients except those who refused the use
of their clinical and laboratory data.
Patients’ electronic health records were reviewed by
infectious diseases residents to collect epidemiological (age,
sex, comorbidities), clinical (symptoms, signs), laboratory
(D-dimer, white blood cells, platelets, C-reactive protein,
procalcitonin), prognostic and diagnostic scores (Padua,
Revised Geneva score, simplified Geneva risk assessment
model, Wells criteria), and radiological data. Data regarding
known risk factors for VTE were collected, such as overt
active cancer, current pregnancy, thrombophilia (hereditary
or acquired), previous VTE, or a temporary predisposing fac-
tor in the previous month including paralysis, paresis, plaster
immobilization of the lower limb, and major surgery [20–22].
All the data were entered in the Lausanne University Hospi-
tal’s electronic database “regCOVID” using the REDCap®
platform (Research Electronic Data Capture v8.5.24, Vander-
bilt University, Tennessee, USA) [23].
The primary outcome was defined as VTE occurrence.
VTE included pulmonary embolism (PE), deep vein throm-
bosis of the limbs (DVT), or thrombosis at other sites, includ-
ing catheter-related thrombosis, confirmed by contrast-
enhanced computed tomography (ceCT) pulmonary angio-
gram or Doppler-echography. No universal screening for
asymptomatic VTE was performed. Hospital-acquired
SARS-CoV-2 infection was defined as the initiation of symp-
toms five days after hospital admission. VTE was analyzed in
two separate groups: upon admission and during hospitaliza-
tion, the latter being also referred to in the literature as
hospital-acquired thrombosis [24]. Based on prior studies
showing that D-dimer could identify patients with poor
prognosis at an early stage of COVID-19, the D-dimer mea-
surement was initially proposed by the institutional guide-
lines in all patients admitted with respiratory insufficiency
[8].
Data on anticoagulation therapy were collected including
the type of molecule: low molecular weight heparin
(LMWH), unfractionated heparin (UFH) and oral anticoag-
ulants (both direct oral anticoagulants and vitamin K antag-
onists), dosage, route, and duration of administration. A
patient was considered to be on anticoagulation treatment
in case of administration of any type of anticoagulation in
prophylactic or therapeutic dosage, for more than 72 h before
VTE diagnosis. Intermediate-dosage thromboprophylaxis
protocol (for creatinineclearance ≥ 30ml/minUFH sc 5,000
UI tid or enoxaparin 40mg bid (<120 kg) or 60mg bid
(≥120 kg); for creatinine clearance <30ml/min UFH iv 200
UI/kg/24 h) was included on April 6, 2020 in the internal rec-
ommendations on thromboprophylaxis in COVID-19
patients admitted in the ICU [25]. Because the level of aware-
ness of VTE complications related to COVID-19 rose rapidly
during the pandemic period as a consequence of the accumu-
lation of reports in the literature, the study period was
divided into three periods: the first period from February
28 to March 25 (low awareness of SARS-CoV-2
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thrombogenic potential), second from March 26 to April 5
(increased level of awareness), and third from April 6 to
May 5 (change in prophylactic anticoagulation in ICU
patients).
Data analyses were performed using the open-source
programming language Python (Python Software Founda-
tion, Wilmington, DE, USA) and the associated libraries for
statistical analysis such as SciPy and StatsModels. Fisher
exact test or chi-square was used for categorical variables,
whereas Mann–Whitney U test was used for numerical ones.
In case of missing data, the univariate analysis included only
patients with available data. Receiver operating characteristic
491 patients with microbiologically documented
SARS-CoV-2 infection
48 refused to consent
443 patients included in the study
41 patients with a thromboembolic event (VTE)
27 PE, 12 DVT, one simultaneous PE and
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Figure 2: Daily number of COVID-19 patients admitted and those with confirmed VTE and CT scan performed upon admission.
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(ROC) curves for VTE development upon admission and
hospitalization were generated for D-dimer, and the optimal
cutoff value was calculated with Youden’s index (Supplemen-
tary Figure 1). Logistic regression was used to determine the
risk factors for VTE development. Odds ratios (ORs) and
95% confidence intervals (CIs) were calculated to evaluate
the strength of any association. All statistical tests were 2-
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(b)
Figure 3: (a), (b) Daily number of COVID-19 patients being hospitalized and those with confirmed VTE and CT scan performed during
hospitalization.
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3. Results
During the study period, 491 patients with microbiologically
documented SARS-CoV-2 infection were admitted to the
hospital. Among them, 48 patients had previously refused
to consent to the use of their clinical data and were excluded.
Thus, a total of 443 patients hospitalized with SARS-CoV-2
infection were included in this study (Figure 1).
Overall, a thromboembolic event was identified in 41
patients (9.3%); 27 patients had PE (four saddle, 10 lobar,
13 segmental or subsegmental), 12 had DVT (seven proximal
and five distal; seven occurring in the lower extremities, two
in the upper extremities, three in the jugular vein), one
patient had simultaneously lobar PE and distal DVT of the
lower limb, and one had portal vein thrombosis associated
with a concomitant episode of acute cholecystitis. All VTE
patients had a D-dimer value measurement the same day of
diagnosis or the day before. Fourteen patients (34.1%) were
diagnosed upon admission (three admitted directly at ICU
and 11 at wards), from whom 11 (78.6%) had PE. Regarding
the 27 patients (65.9%) with VTE during hospitalization,
VTE was diagnosed at a median of eight days from admis-
sion; from these patients, nine were hospitalized in medical
wards and 18 in the ICU. Supplementary Table 1 provides
a descriptive analysis of the characteristics of all patients
with VTE.
A total of 171 chest ceCT scans were performed in 135
patients (30.5%) during the study period. Figure 2 illustrates
the daily number of patients who had a CT scan performed
upon admission and the number of VTE diagnoses out of
the total number of patients admitted on the same day.
Figures 3(a) and 3(b) show the daily proportion of patients
with a CT scan performed during hospitalization out of the
total number of patients present in the hospital and the num-
ber of VTE diagnoses on the same day. Upon admission, we
observed an increase in performed ceCT scans (P < 0:001)
and VTE diagnoses per 100 admissions (P 0.020) during
the second period as compared to the first; no difference in
ceCT scans (P 0.464) or VTE diagnoses (P 1.000) was
observed between the second and third period. During hospi-
talization, ceCT scans increased steadily throughout the three
periods. However, while VTE diagnoses per 1,000-patient-
days increased from the first to second period (P 0.041), a
tendency to decrease was observed from the second to the
third one (P 0.056) (Table 1).
Patients’ characteristics and univariate analysis of predic-
tors of VTE upon admission are shown in Table 2. D-dimer
values were available for 363 patients (81.9%). Multivariate
analysis revealed D-dimer value > 3,120 ng/ml (P < 0:001;
OR 15.8, 95% CI 4.7-52.9) and duration of 8 days or more
from COVID-19 symptoms onset to presentation (P 0.020;
OR 4.8, 95% CI 1.3-18.3) to be independently associated with
VTE upon admission. Table 3 depicts the patients’ character-
istics and univariate analysis of predictors of VTE during
hospitalization. D-dimer values were available for 373
(86.9%). D-dimer value > 5,611 ng/ml (P < 0:001; OR 6.3,
95% CI 2.4-16.2) and mechanical ventilation (P < 0:001; OR
5.9, 95% CI 2.3-15.1) were independent predictors for VTE
during hospitalization. The abovementioned D-dimer values
were the optimal cutoffs defined by ROC-curve analysis
(Supplementary Figure 1).
D-dimer values were available for 363 patients (81.9%)
upon admission and for 373 (86.9%) during hospitalization.
Table 4 shows the performance of different combinations of
D-dimer values and Wells score for PE in predicting VTE
upon admission. The presence of either a Wells score
forPE ≥ 2points or a D-dimervalue ≥ 1,000 ng/mlis the most
sensitive for PE diagnosis (sensitivity 92.9%, specificity
46.9%). On the other hand, a D-dimer value ≥ 3,000 ng/l
combined with a Wells score for PE ≥ 2 was associated with
the highest specificity (sensitivity 57.1%, specificity 91.6%,
accuracy 0.905), while D-dimer value ≥ 3,000 ng/l alone was
less specific for this diagnosis (sensitivity 71.4%, specificity
87.9%, accuracy 0.797). Figure 4 (patients in the emergency
room) shows the D-dimer values for the prediction of VTE
upon admission (P < 0:001), while Figures 4(b) (during hos-
pitalization in wards, P < 0:001) and (c) (during hospitaliza-
tion in the ICU, P < 0:001) depict the peak D-dimer value for
Table 1: CT-scan and VTE per 100 admissions or per 1,000-patient-days in the three periods.
Period 1
February 28 to March 25
Period 2
March 26 to April 5
Period 3
April 6 to May 7
Pa Pb
VTE upon admission
ceCT scan performed 18 34 31 <0.001 0.464
VTE 2 8 4 0.020 1.000
Admissions 185 145 113 - -
ceCT scan per 100 admissions 9.7 23.4 27.4 - -
VTE per 100 admissions 1.1 5.5 3.5 - -
VTE during hospitalization
ceCT-scan performed 10 20 56 0.328 0.041
VTE 2 14 11 0.016 0.056
Patient days 1111 1528 2543 - -
ceCT scan per 1,000-patient-days 9.0 13.1 22.0 - -
VTE per 1,000-patient-days 1.8 9.2 4.3 - -
ceCT: contrast-enhanced computed tomography; VTE: venous thromboembolism. aComparison of periods 1 and 2. bComparison of periods 2 and 3.
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Table 2: Patients’ characteristics and univariate analysis of factors associated with VTE upon admission.
Characteristics Without VTE (n = 429) VTE (n = 14) P
Demographics
Age (years) 69.0 (55.0-81.0) 59.0 (49.5-70.0) 0.051
Male gender 246 (57.3%) 10 (71.4%) 0.412
Comorbidities
Diabetes mellitus 105 (24.5%) 4 (28.6%) 0.754
Chronic obstructive pulmonary disease 33 (7.7%) 1 (7.1%) 1.000
Chronic heart failure 38 (8.9%) 1 (7.1%) 1.000
Chronic kidney disease 65 (15.2%) 3 (21.4%) 0.460
Cirrhosis 16 (3.7%) 0 (0.0%) 1.000
Malignancy (hematological or solid organ) 51 (11.9%) 0 (0.0%) 0.386
Previous VTE 34 (7.9%) 3 (21.4%) 0.103
Obesity 104 (24.2%) 4 (28.6%) 0.753
Charlson comorbidity index 5.0 (2.0-6.0) 2.0 (1.0-4.0) 0.077
Symptomsa
Community-acquired infection 362 (84.4%) 13 (92.9%) 0.705
Days from symptoms onset 7.0 (3.0-10.0) 10.0 (8.2-12.2) 0.002
Duration of symptoms ≥8 days 162 (37.8%) 11 (78.6%) 0.004b
Fever 277 (64.6%) 11 (78.6%) 0.396
Cough 280 (65.3%) 10 (71.4%) 0.779
Dyspnea 234 (54.5%) 12 (85.7%) 0.027
Thoracic pain 49 (11.4%) 5 (35.7%) 0.019
Signsa
Temperature (°C) 38.1 (37.3-38.7) 37.9 (37.0-38.5) 0.301
Systolic blood pressure (mmHg) 117.0 (102.2-127.0) 107.0 (100.0-130.0) 0.590
Heart rate (beats/min) 92.0 (82.0-104.0) 103.0 (87.0-111.0) 0.177
Respiratory rate (breath/min) 25.0 (21.0-31.0) 26.0 (24.0-29.0) 0.805
Glasgow Coma Scale 15.0 (15.0-15.0) 15.0 (15.0-15.0) 0.212
Laboratory findingsa
White blood cells (G/l) 6.1 (4.7-8.8) 10.0 (5.9-13.2) 0.014
D-dimer (ng/ml) (among 363 patients) 1039.0 (549.0-2020.0) 3610.0 (1934.0-7093.8) <0.001
D-dimer >3,120 ng/ml 52 (12.1%) 10 (71.4%) <0.001b
C-reactive protein (mg/l) (among 413 patients) 61.5 (21.0-124.2) 91.0 (53.0-187.0) 0.225
Procalcitonin (ng/ml) (for 321 patients) 0.2 (0.1-0.4) 0.2 (0.1-0.5) 0.876
Radiological findingsa
Normal X-ray or ceCT scan 92 (21.4%) 3 (21.4%) 1.000
Bilateral infiltrates on X-ray or ceCT scan 247 (57.6%) 11 (78.6%) 0.168
Prior administration of therapeutic or prophylactic anticoagulation 88 (20.5%) 0 (0.0%) 0.083
Scores (prognostic or diagnostic)a
Padua score 6.0 (5.0-7.0) 6.0 (5.0-6.0) 0.814
Revised Geneva score 5.0 (3.0-6.0) 5.0 (4.2-6.8) 0.205
Revised Geneva score ≥ 4 314 (73.2%) 12 (85.7%) 0.373
Simplified Geneva risk assessment model 5.0 (4.0-6.0) 5.0 (4.2-5.0) 0.809
Simplified Geneva risk assessment model ≥ 3 396 (92.3%) 12 (85.7%) 0.305
Wells criteria 1.0 (0.0-1.5) 3.8 (1.9-4.5) <0.001
Wells criteria ≥ 2 97 (22.6%) 10 (71.4%) <0.001
Outcome
Type of discharge
Discharge at home 217 (50.6%) 10 (71.4%)
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non-VTE and the last value before the diagnosis of the
thrombotic event for VTE patients.
4. Discussion
In this study, the rate of VTE among hospitalized patients
with COVID-19 was 9.3% which is similar to that reported
previously among COVID-19 inpatients [14, 26] and much
higher than the VTE incidence previously described among
inpatients with influenza and influenza-associated pneumo-
nia (1.0-3.4%) [27, 28], while no published data are available
concerning the VTE prevalence in previous coronavirus
infections SARS-CoV-1 and MERS-CoV.
Of particular note, a large proportion of VTE was diag-
nosed upon admission (14 out of 443 patients; 3.2%). To
the best of our knowledge, this is the first study to find an
association between a prolonged duration of COVID-19-
related symptoms and VTE diagnosis upon admission. This
observation could be explained by a greater degree of immo-
bilization (possibly due to infection control measures) and/or
a longer exposure to the systemic inflammatory response
[29], contributing to an increased risk of VTE already present
before admission. As previously shown, the peak of systemic
inflammatory response reflected on the greatest severity of
lung lesions (ground-glass opacities, consolidations) was
found 9-13 days from the onset of the initial symptoms
[29]. This observation should prompt evaluation of throm-
boprophylaxis for some patients in the outpatient setting.
Similarly, the risk of thrombosis after discharge still needs
to be assessed, as it may persist for several weeks after acute
infection by analogy with other respiratory infections [30],
requiring evaluation of a prolonged duration of thrombopro-
phylaxis after discharge.
In our study, ceCT scans and other diagnostic testing
were performed as part of standard care, according to physi-
cians’ discretion; 30.5% of patients had at least one ceCT scan
performed, the percentage comparable to previous reports
[14, 31]. During the study period, an interesting pattern
was observed with three distinct periods. ceCT scans were
less frequently performed during the initial period associated
with fewer VTE diagnoses. This finding could reflect a lower
level of awareness of the risk of thromboembolic complica-
tions in the setting of COVID-19. Chest ceCT scans were
more frequently performed during the second period, with
a subsequent rise in VTE diagnoses (both upon admission
and during hospitalization). Finally, in the third period,
despite the high number of ceCT scans performed, a trend
towards fewer VTE diagnoses was observed during hospital-
ization. This pattern could reflect the effect of more aggres-
sive anticoagulation strategies implemented in ICU-
hospitalized patients on April 6, 2020 [25].
Hospitalization in the ICU and especially mechanical
ventilation were associated with VTE occurrence. The high
rate in the ICU setting (22.3%; 21 out of 94 patients) is con-
sistent with the current bibliography, but seems lower than
most of the previous studies, especially compared to a recent
meta-analysis showing an overall rate of 30.4% among ICU
patients [12, 13, 26]. Interestingly, Helms et al. reported a
higher rate in patients with COVID-19-related acute respira-
tory distress syndrome (ARDS) in comparison with patients
with ARDS of other causes [9]. The importance of these clin-
ical incidence rates is further highlighted by a recent series of
12 consecutive autopsy reports showing the presence of VTE
in 58% of cases, who went unrecognized before death [32].
Among patients hospitalized in wards, the incidence of
VTE (5.9%; 20 out of 335 patients) was also inferior to the
one reported in the abovementioned meta-analysis (13%)
[25, 26]. These lower rates in our study could be explained
by the intensification of prophylactic anticoagulation during
the study period, as well as the earlier hospitalization of many
patients presenting less severe complications compared to
other countries with a more significant healthcare overload
[14].
While an isolated D-dimer value alone cannot reliably be
used to assess the indication for ceCT scan, it helps to estab-
lish useful strategies for PE diagnosis. According to our data,
PE was less likely upon admission in case of a Wells score of
≤2 points and a D-dimer value of ≤1,000 ng/ml, and ceCT
scan may therefore not be required. Moreover, when diag-
nostic imaging for PE is not possible, empiric therapeutic
anticoagulation should be considered if the Wells score is
≥2 points and the D-dimer value is ≥3,000 ng/l. The D-
dimer values upon admission and during hospitalization
(ward, ICU) showed a significant difference among patients
with VTE and those without (Figure 4). Defining a more
accurate D-dimers’ threshold could be an interesting diag-
nostic strategy, but requires further prospective evaluation.
Several limitations of our work are worth noting. First,
this is a retrospective, single-center study; thus, the results
may not be safely generalized. Second, suspicion and diagno-
sis of VTE were at clinicians’ discretion, and no active sur-
veillance was systematically performed during the study
period. Therefore, the incidence of VTE was probably under-
estimated, as suggested by the abovementioned autopsy
Table 2: Continued.
Characteristics Without VTE (n = 429) VTE (n = 14) P
Transfer to other acute care hospital 48 (11.2%) 2 (14.3%)
Rehabilitation 82 (19.1%) 0 (0.0%)
Still hospitalized 23 (5.4%) 1 (7.1%)
Death 59 (13.8%) 1 (7.1%) 0.704
Length of hospitalization 10.9 (4.0-13.0) 9.9 (3.0-13.0) 0.688
Data are number (%) of patients or median (Q1-Q3).
aUpon admission. bFactors included in the multivariate analysis. ceCT: contrast-enhanced computed
tomography.
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Table 3: Patients’ characteristics and univariate analysis of factors associated with VTE during hospitalization.
Characteristics Without VTE (n = 402) VTE (n = 27) P
Days at riska 8.0 (4.0-12.0) 8.0 (6.5-12.0) 0.319
Demographics
Age (years) 70.0 (55.0-81.0) 62.0 (58.0-68.5) 0.039
Male gender 224 (55.7%) 22 (81.5%) 0.009b
Comorbidities
Diabetes mellitus 99 (24.6%) 6 (22.2%) 1.000
Chronic obstructive pulmonary disease 29 (7.2%) 4 (14.8%) 0.144
Chronic heart failure 36 (9.0%) 2 (7.4%) 1.000
Chronic kidney disease 65 (16.2%) 0 (0.0%) 0.022
Cirrhosis 15 (3.7%) 1 (3.7%) 1.000
Malignancy (hematological or solid organ) 48 (11.9%) 3 (11.1%) 1.000
Previous VTE 33 (8.2%) 1 (3.7%) 0.712
Obesity 96 (23.9%) 8 (29.6%) 0.491
Charlson comorbidity index 5.0 (2.0-7.0) 3.0 (2.0-5.0) 0.025
Laboratory findingsc
White blood cells (G/l) 7.2 (5.4-10.2) 8.6 (7.4-9.7) 0.107
D-dimer (ng/ml) (among 373 patients) 1252.5 (629.8-2722.5) 10835.0 (4748.5-16679.0) <0.001
D − dimer > 5611 ng/ml 48 (11.9%) 17 (63.0%) <0.001b
C-reactive protein (mg/l) (among 411 patients) 74.5 (28.2-146.8) 51.0 (25.0-213.0) 0.630
Procalcitonin (ng/ml) (for 344 patients) 0.2 (0.1-0.5) 0.2 (0.1-0.7) 0.696
Radiological findingsc
Normal X-ray or ceCT scan 90 (22.4%) 0 (0.0%) 0.012
Bilateral infiltrates on X-ray or ceCT scan 226 (56.2%) 26 (96.3%) <0.001
Complications/treatmentsc
ICU admission 76 (18.9%) 18 (66.7%) <0.001
Mechanical ventilation 55 (13.7%) 18 (66.7%) <0.001b
Acute respiratory distress syndrome 76 (18.9%) 17 (63.0%) <0.001
Prior anticoagulationd
No anticoagulation 88 (21.9%) 8 (29.6%) 0.345
Prophylactic anticoagulatione 250 (62.2%) 17 (63.0%) 0.901
Therapeutic anticoagulation 72 (17.9%) 1 (3.7%) 0.064
Scores (prognostic or diagnostic)
Padua score 6.0 (5.0-7.0) 5.0 (5.0-6.0) 0.350
Revised Geneva score 5.0 (3.0-6.0) 4.0 (3.0-6.5) 0.442
Revised Geneva score ≥ 4 299 (74.4%) 15 (55.6%) 0.056
Simplified Geneva risk assessment model 5.0 (4.0-6.0) 5.0 (4.5-5.0) 0.418
Simplified Geneva risk assessment model ≥ 3 370 (92.0%) 26 (96.3%) 0.710
Wells criteria 1.2 (0.0-1.5) 3.0 (3.0-3.5) <0.001
Wells criteria ≥ 2 78 (19.4%) 21 (77.8%) <0.001
Outcome
Type of discharge
Discharge at home 208 (51.7%) 9 (33.3%)
Transfer to other acute care hospital 41 (10.2%) 7 (25.9%)
Rehabilitation 78 (19.4%) 4 (14.8%)
Still hospitalized 18 (4.5%) 5 (18.5%)
Death 57 (14.2%) 2 (7.4%) 0.561
Length of hospitalization 9.9 (4.0-12.0) 27.9 (16.0-24.0) <0.001
Data are number (%) of patients or median (Q1-Q3).
aFrom admission until VTE. bFactors included in the multivariate analysis. cLast value before VTE
diagnosis for patients with VTE; peak value during hospitalization for patients without VTE. dFrom admission until 72 h before VTE for VTE patients;
from admission to discharge for patients without VTE. eCharacterized as a dose lesser to the therapeutic one. ceCT: contrast-enhanced computed tomography.
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reports [32]. Third, the VTE definition differs from classical
VTE studies, which exclude VTE occurring at other sites than
the lower limbs and pulmonary embolism. However, all pre-
vious studies in COVID-19 setting included VTE of all loca-
lisations [9, 11, 12, 13, 14]. Finally, we provided a follow-up
only for the duration of the hospitalization, whereas a longer
follow-up of at least three months from infection onset may
be desirable.
5. Conclusion
VTE seems to be a common complication of SARS-CoV-2
infection already upon admission and during hospitalization,
especially in ICU. Time from symptoms’ onset to admission
seems to be a major clinical risk factor for patients diagnosed
for VTE upon admission. Our study provides for the first
time a 3-phase timeline illustration of the impact of increased
awareness for VTE and the beneficial role of a subsequent
intensification of the preventive anticoagulation strategies
in patients requiring hospitalization because of COVID-19.
The combination of Wells’ score with the D-dimer value at
admission can be a useful tool to guide empiric anticoagula-
tion therapy when diagnostic imaging is not possible or avail-
able. Furthermore, based on the high rate of early VTE
present upon admission, there appears to be an urgent need
to study the potential benefit of thromboprophylaxis for
patients with SARS-CoV-2 infection in the ambulatory
setting.
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Table 4: Performance of different combinations of D-dimer values and Wells score for PE in predicting VTE upon admission.
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy
D-dimer value ≥ 3,000 ng/ml 71.4 87.9 99.0 87.4 0.797
Wells score for PE ≥ 2 points 71.4 77.4 9.3 98.8 0.772
Wells score for PE ≥ 2 points and D-dimer value ≥ 3,000 ng/ml 57.1 91.6 18.2 98.5 0.905
Wells score for PE ≥ 2 points or D-dimer value ≥1,000 ng/ml 92.9 46.9 5.4 99.5 0.483



























Figure 4: (a) D-dimer values (ng/ml) in patients in the emergency room for the prediction of VTE upon admission (P < 0:001). (b) D-dimer
values (ng/ml) for the prediction of VTE during hospitalization in wards (P < 0:001). (c) D-dimer values (ng/ml) for the prediction of VTE
during hospitalization in ICU (P < 0:001). For (b) and (c), the peak D-dimer value during their stay was used for patients without VTE and the




SARS-CoV-2: Severe Acute Respiratory Syndrome Corona-
virus 2
UFH: Unfractionated heparin
VTE: Venous thromboembolic events.
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